REGENXBIO to Present at Upcoming Investor Conferences
October 03 2017 - 7:00AM
REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage
biotechnology company seeking to improve lives through the curative
potential of gene therapy based on its proprietary NAV® Technology
Platform, today announced that it will present at the following
October investor conferences:
Chardan Inaugural Gene Therapy
ConferenceDate: Tuesday, October 10,
2017Location: The Westin New York Grand Central
HotelFireside chat: Tuesday, October 10, 2017 at
9:30 a.m. ETPanel: Gene Therapies: Pricing and
Other Commercial Considerations; Tuesday, October 10, 2017 at 4:15
p.m. ET
Jefferies Gene Therapy Technology Investor
SummitDate: Thursday, October 12,
2017Location: The Westin New York Grand Central
HotelFireside chat: Thursday, October 12, 2017 at
3:10 p.m. ET
A live webcast of each presentation can be accessed in the
Investors section of REGENXBIO’s website at www.regenxbio.com. An
archived replay of each webcast will be available on the same
website for approximately 30 days following the presentation. In
addition, REGENXBIO senior management will be holding one-on-one
meetings at each of the conferences.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO’s NAV® Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
CONTACT:
Investors Natalie Wildenradt, 646-681-8192
natalie@argotpartners.com
Media Adam Pawluk, 202-591-4063
apawluk@jpa.com
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
REGENXBIO (NASDAQ:RGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024